We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
+11.54%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$359M
AUM Growth
+$47.7M
Cap. Flow
+$72.2M
Cap. Flow %
20.13%
Top 10 Hldgs %
73.89%
Holding
44
New
12
Increased
4
Reduced
14
Closed
8

Top Buys

Rank Stock Value
1
NKTX icon
Nkarta
NKTX
+$60M
2
CVAC
CureVac
CVAC
+$20.7M
3
COGT icon
Cogent Biosciences
COGT
+$14.8M
4
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$9.03M
5
EQ icon
Equillium
EQ
+$8.7M

Top Sells

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$20.5M
2
SWTX
SpringWorks Therapeutics
SWTX
+$6.79M
3
ARAV
Aravive, Inc. Common Stock
ARAV
+$6.71M
4
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$5.28M
5
PVLA
Palvella Therapeutics
PVLA
+$5.2M

Sector Composition

Rank Sector Weight
1 Healthcare 98.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FULC icon
26
Fulcrum Therapeutics
FULC
$297M
$2.33M 0.65%
294,118
– –
RCKT icon
27
Rocket Pharmaceuticals
RCKT
$394M
$2.28M 0.64%
99,643
-38,554
-28% -$950K
AIMT
28
DELISTED
Aimmune Therapeutics
AIMT
$2M 0.56%
58,142
-174,429
-75% -$3.71M
ATXS
29
DELISTED
Astria Therapeutics
ATXS
$1.86M 0.52%
50,000
– –
SPRO icon
30
Spero Therapeutics
SPRO
$73M
$1.79M 0.5%
+160,000
New +$1.89M
UROV
31
DELISTED
Urovant Sciences Ltd.
UROV
$1.47M 0.41%
157,480
– –
HOOK
32
DELISTED
HOOKIPA Pharma
HOOK
$1.1M 0.31%
11,660
-28,365
-71% -$2.89M
KALV
33
DELISTED
KalVista Pharmaceuticals
KALV
$1.06M 0.3%
84,087
-84,087
-50% -$1.05M
BNTX icon
34
BioNTech
BNTX
$23.5B
$879K 0.25%
+12,700
New +$911K
NGM
35
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$580K 0.16%
36,451
-12,151
-25% -$222K
AMRN
36
Amarin Corp
AMRN
$303M
$105K 0.03%
1,250
-1,250
-50% -$150K
AKRO
37
DELISTED
Akero Therapeutics
AKRO
– –
-22,234
Closed -$554K
ASMB icon
38
Assembly Biosciences
ASMB
$529M
– –
-2,478
Closed -$694K
SLNO
39
DELISTED
Soleno Therapeutics
SLNO
– –
-50,000
Closed -$1.67M
PVLA
40
Palvella Therapeutics
PVLA
$2.27B
– –
-20,253
Closed -$5.2M
ARAV
41
DELISTED
Aravive, Inc. Common Stock
ARAV
– –
-576,066
Closed -$6.71M
BLU
42
DELISTED
BELLUS Health Inc.
BLU
– –
-333,631
Closed -$3.45M
PRNB
43
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
– –
-342,946
Closed -$20.5M
PTLA
44
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-318,429
Closed -$5.28M
1
2

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return
MSA
Mason Street Advisors Milwaukee, Wisconsin $1.02B AUM 8.35% 1-Year Est. Return
TBA
Tower Bridge Advisors Conshohocken, Pennsylvania $1.04B AUM 23.66% 1-Year Est. Return

Samsara BioCapital's Q3 2020 Portfolio in Review

As of Q3 2020, Samsara BioCapital held 44 positions worth $359M, up 15% from $311M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Samsara BioCapital deployed $72.2M of net new capital in Q3 2020, opening 12 new positions and adding to 4 existing holdings. Its largest new stake was Nkarta: 2,034,703 shares worth $61.2M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier.

On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $6.79M trimmed.

  • Samsara BioCapital's largest Q3 2020 buy was Nkarta: 2,034,703 shares worth $61.2M.
  • Samsara BioCapital added most to Odonate Therapeutics, Inc. Common Stock in Q3 2020, an estimated $9.03M increase.
  • Samsara BioCapital's biggest Q3 2020 reduction was SpringWorks Therapeutics, cutting an estimated $6.79M.
  • Samsara BioCapital fully exited Principia Biopharma Inc. Common Stock in Q3 2020, selling an estimated $20.5M.
  • Samsara BioCapital's ten largest holdings make up 74% of its $359M portfolio in Q3 2020.
  • Samsara BioCapital opened 12 new positions and closed 8 in Q3 2020.
  • Samsara BioCapital's portfolio value rose 15% quarter-over-quarter to $359M.

Based on Samsara BioCapital's 13F filing for Q3 2020, filed 16 Nov 2020.